- Home
- EPSN vs ELDN Comparison
EPSN vs ELDN Comparison
Compare EPSN & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPSN
- ELDN
- Stock Information
- Founded
- EPSN 2005
- ELDN 2004
- Country
- EPSN Canada
- ELDN United States
- Employees
- EPSN N/A
- ELDN N/A
- Industry
- EPSN Oil & Gas Production
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- EPSN Energy
- ELDN Health Care
- Exchange
- EPSN Nasdaq
- ELDN Nasdaq
- Market Cap
- EPSN 175.3M
- ELDN 202.4M
- IPO Year
- EPSN N/A
- ELDN N/A
- Fundamental
- Price
- EPSN $5.56
- ELDN $2.58
- Analyst Decision
- EPSN Strong Buy
- ELDN Strong Buy
- Analyst Count
- EPSN 1
- ELDN 2
- Target Price
- EPSN $7.00
- ELDN $12.50
- AVG Volume (30 Days)
- EPSN 127.1K
- ELDN 996.8K
- Earning Date
- EPSN 08-13-2025
- ELDN 08-22-2025
- Dividend Yield
- EPSN 4.56%
- ELDN N/A
- EPS Growth
- EPSN N/A
- ELDN N/A
- EPS
- EPSN 0.23
- ELDN N/A
- Revenue
- EPSN $44,016,087.00
- ELDN N/A
- Revenue This Year
- EPSN $41.35
- ELDN N/A
- Revenue Next Year
- EPSN N/A
- ELDN N/A
- P/E Ratio
- EPSN $27.96
- ELDN N/A
- Revenue Growth
- EPSN 45.90
- ELDN N/A
- 52 Week Low
- EPSN $4.95
- ELDN $2.38
- 52 Week High
- EPSN $8.50
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- EPSN 29.50
- ELDN 34.61
- Support Level
- EPSN $5.33
- ELDN $2.54
- Resistance Level
- EPSN $6.50
- ELDN $2.82
- Average True Range (ATR)
- EPSN 0.24
- ELDN 0.21
- MACD
- EPSN -0.02
- ELDN -0.09
- Stochastic Oscillator
- EPSN 17.09
- ELDN 15.00
About EPSN Epsilon Energy Ltd. Common Share
Epsilon Energy Ltd is engaged in the acquisition, development, gathering, and production of natural gas and oil reserves. The operating segments of the company include Upstream segment activities including acquisition, development, and production of natural gas reserves on properties within the United States. The Gas Gathering segment partners with two other companies to operate a natural gas gathering system, and the corporate segment activities include corporate listing and governance functions of the corporation. The company generates revenue from the sale of crude oil and natural gas.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.